January 11, 2016 — As Medicaid programs in at least 34 states restrict coverage for Harvoni and Sovaldi, a growing number of patients with hepatitis C are being told they are not sick enough for treatment.
Indiana’s Medicaid program denied coverage for Harvoni because she does not yet have liver damage. According to her attorney: “If something is medically necessary, it’s medically necessary and must be covered by the Medicaid program.”
In November, the Center for Medicare and Medicaid Services sent a letter reminding states that they cannot restrict coverage for drugs that are prescribed for medically necessary conditions.
The problem is that Sovaldi and Harvoni are extremely expensive — up to $95,000 for a 12-week treatment with Harvoni. According to the Chicago Tribune, the same $1,000 pill sells for just $4 in India.
Critics of the restrictions say the up-front costs are justified by the long-term benefits, including a reduced cost of treating complications and eliminating the risk of transmitting hepatitis C to another person.
The World Health Organization (WHO) estimates that 3 million people in the United States have hepatitis C, out of 150 million worldwide. Hepatitis C is a highly-contagious virus that spreads in blood and bodily fluids, often on dirty needles or medical equipment. Infection causes liver inflammation and scarring that can lead to liver failure and death.
Do I have a Harvoni Lawsuit?
The Schmidt Firm, PLLC is currently accepting cases in all 50 states. If you or somebody you know has hepatitis C and was denied insurance coverage, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.